zinc finger protein 355, pseudogeneGenealiases: PRED65 · ZNF834
Q-omics provides the consensus-scored ZNF355P profile across patient tissues and cancer cell-line models. ZNF355P expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in TGCT. Among the 18 cancer types available for tumor–normal comparison, ZNF355P is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, ZNF355P RNA expression shows 5,596 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight TGCT, KIRC, and STAD as cancer lineages where ZNF355P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF355P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF355P survival associations across molecular data types. ZNF355P RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF355P RNA expression–survival associations across cancer types. High ZNF355P expression shows unfavorable associations in TGCT, KIRC, ESCA, LUAD, PCPG and DLBC. The TGCT Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify TGCT as the clearest survival context for ZNF355P RNA expression.
This table summarizes ZNF355P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF355P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF355P shows lower tumor expression in KIRC and higher tumor expression in LUAD. The KIRC box plot shows higher ZNF355P RNA expression in normal versus tumor tissue (log2 FC = −0.005, t-test p = .001).
This table shows molecular features associated with ZNF355P in patient tissues and cancer cell lines. In patient samples, ZNF355P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
